This line of thinking for COVID-19 and its most severe phenotypes also introduces targeted therapies such as DNase1, neutrophil elastase small molecule inhibitors-sivelestat, alvelestat and Bay-8550, inhibitors of cell free DNA re-entry like interleukin-26 and NET inhibitory peptides [42] into the dialogue of early pharmacological interventions that may offer both near-and long-term benefit in patients with COVID-19 (reviewed in Becker RC) [43]. The gene discussed is IL26; the disease is COVID-19.